Diamics is a privately-held company formed in collaboration with world-wide strategic partners to combine unique biochemical and molecular approaches to cancer detection systems. The company’s molecular approach can be employed for the detection of cervical, ovarian, prostate, lung, and bladder cancers. Diamics’ initial focus is on introducing a proprietary mapping system for the detection of cervical cancer that will be used as an adjunct to Pap testing in developed countries such as the United States. In developing countries, the Diamics system will be used to make cervical cancer screening accessible to the many women for whom Pap testing is not available. Diamics has undertaken the development of a new screening system which utilizes proven molecular technologies that will result in significant benefits to patients, laboratories, obstetrician/gynecologists, and governments.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 07/19/07 | Series B | 6M | Inverness Medical Innovations, Keirestu Forum | Unknown |